Search Results

You are looking at 21 - 30 of 272 items for :

  • "neutropenia" x
Clear All
Full access

David C. Dale

Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 13 Pettengell R Gurney H Radford JA

Full access

Eric J. Bow

neutropenia and fever] . Rev Esp Quimioter 2001 ; 14 : 75 – 83 . 3 Hughes WT Armstrong D Bodey GP . 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer . Clin Infect Dis 2002 ; 34 : 730 – 751 . 4

Full access

Kimberly Rose Hedstrom, Margaret Rausa, Eric Gratias and Stephen Hamilton

Background: The National Comprehensive Cancer Network (NCCN) establishes standard of care for patients receiving anticancer therapy, and classifies regimens based on febrile neutropenia (FN) and emesis risks. eviCore healthcare licenses NCCN

Full access

Robert E. Smith Jr.

first-line treatment in advanced colorectal cancer . J Clin Oncol 2000 ; 18 : 2938 – 2947 . 67. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients

Full access

Jeffrey Crawford, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A. Griffiths, Shannon Hough, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L. Burns and Lenora Pluchino

used to reduce the incidence of neutropenia. Neutropenia is defined as an absolute neutrophil count (ANC) of <500 neutrophils/mcL or an ANC of <1,000 neutrophils/mcL and a predicted decline ≤500 neutrophils/mcL over the next 48 hours. Neutropenia can

Full access

Gary H. Lyman and David C. Dale

M yeloid growth factors have been used for more than 20 years to ameliorate myelotoxicity after cancer chemotherapy and to prevent infections in patients with chronic neutropenia. Almost all data on long-term outcomes come from studies of

Full access

Gary H. Lyman

Dr. Lyman has received research grant support from Amgen and GlaxoSmithKline and is on the speakers' bureau of Amgen and OrthoBiotech. References 1 Lyman GH Kuderer NM . Epidemiology of febrile neutropenia . Support Cancer Ther

Full access

Jeffrey Crawford, David C. Dale, Nicole M. Kuderer, Eva Culakova, Marek S. Poniewierski, Debra Wolff and Gary H. Lyman

. Talcott JA Siegel RD Finberg R Goldman L . Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule . J Clin Oncol 1992 ; 148 : 2561 – 2568 . 2. Kuderer NM Dale DC Crawford JC

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Pamela Sue Becker, Douglas W. Blayney, Spero R. Cataland, Mark L. Heaney, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Brandon McMahon, Hope S. Rugo, Ayman A. Saad, Lee S. Schwartzberg, Sepideh Shayani, David P. Steensma, Mahsa Talbott, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland, Mary Dwyer and Maria Ho

Neutropenia (<500 neutrophils/mcL or <1000 neutrophils/mcL and a predicted decline to ≤500/mcL over the next 48 h) and resulting febrile neutropenia (FN; ≥38.3°C orally or ≥38.0°C over 1 h) can be induced by myelosuppressive chemotherapy. FN, in turn, is a

Full access

Jacqueline N. Poston and Pamela S. Becker

Acute Myeloid Leukemia The 2 key goals of myeloid growth factor (MGF) use in the management of acute myeloid leukemia (AML) have been (1) a theoretical benefit for “priming” to improve efficacy of chemotherapy, and (2) reduction of neutropenia